论文部分内容阅读
OBJECTIVE:To investigate the therapeutic effects of Jiazhu decoction (JZD) in combination with cyclophosphamide (CTX) on the growth of breast cancer in mice and to explore the possible molecular mechanisms of action.METHODS:BALB/c mice were randomly divided into four groups of 10 (untreated model group,JZD group,CTX group,and JZD + CTX group) and subcutaneously injected with 4T1 mouse breast cancer cells.Tumors were allowed to establish for ～7 d before initiation of treatment with CTX (100 mg/kg every week by intraperitoneal injection) and/or JZD (0.015 mL of 1.65 g/mL crude drug,administered daily by gavage).The model group received equivalent volumes of vehicle on the same schedules.Tumor volumes were measured every 3 d.Mice were sacrificed after 3 weeks of treatment,and tumors were excised and subjected to RT-qPCR and west blot analysis to evaluate expression of the Wnt/ β-catenin signaling pathway components β-catenin,c-Myc,and cyclin D1 at the mRNA and protein levels.RESULTS:The mean tumor volume was smaller and the growth rate was slower in the CTX and JZD + CTX groups compared with the model group (P ＜ 0.05),and in the JZD + CTX group compared with the CTX and JZD groups (P＜ 0.05).Tumor growth was inhibited by 35.4％ and 48.1％ by CTX and JZD + CTX treatment,respectively (P＜ 0.001).The expression of β-catenin,c-Myc,and cyclin D1 mRNA and protein in tumors was significantly lower in mice treated with JZD or JZD + CTX compared with the untreated mice (P ＜ 0.05),and was significantly lower in mice treated with JZD + CTX compared with either JZD or CTX alone (P ＜ 0.05).CONCLUSION:JZD inhibited the growth of mouse breast cancer cells in vivo,possibly by reducing the expression of β-catenin,c-Myc,and cyclin D1.Combination therapy with JZD plus CTX had a more potent inhibitory effect on breast cancer growth compared with either agent alone.